SCHEMBL10698961

SCHEMBL10698961

C[C@@]12CCC[C@H]1[C@@H]1CCC3CC(C(=O)O)CC[C@]3(C)[C@H]1CC2

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN1 Q05586 7/20 0.68
GRIN2B Q13224 7/20 0.68
NR1I3 Q14994 1/20 0.67
CDK5 Q00535 1/20 0.64
CDK5R1 Q15078 1/20 0.64
SRD5A2 P31213 1/20 0.60
G6PD P11413 2/20 0.45
MEN1 O00255 1/20 0.45
GABRP O00591 1/20 0.45
GABRD O14764 1/20 0.45
GMNN O75496 1/20 0.45
LMNA P02545 1/20 0.45
GABRA1 P14867 1/20 0.45
GABRB1 P18505 1/20 0.45
GABRG2 P18507 1/20 0.45
GABRB3 P28472 1/20 0.45
GABRA5 P31644 1/20 0.45
GABRA3 P34903 1/20 0.45
GABRA2 P47869 1/20 0.45
GABRB2 P47870 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11667307 1.00 GRIN1 (0.68) GRIN1GRIN2BNR1I3CDK5CDK5R1
SCHEMBL6579072 0.86 GRIN1 (0.71) GRIN1GRIN2BNR1I3CDK5CDK5R1
SCHEMBL28226182 0.83 GRIN1 (0.60) GRIN1GRIN2BNR1I3CDK5CDK5R1
SCHEMBL6682882 0.83 GRIN1 (0.56) GRIN1GRIN2BNR1I3CDK5CDK5R1
SCHEMBL6682878 0.83 GRIN1 (0.56) GRIN1GRIN2BNR1I3CDK5CDK5R1
SCHEMBL17735543 0.81 CDK5 (0.70) GRIN1GRIN2BNR1I3CDK5CDK5R1
SCHEMBL20781172 0.81 NR1I3 (1.00) GRIN1GRIN2BNR1I3CDK5CDK5R1
SCHEMBL11128263 0.81 NR1I3 (1.00) GRIN1GRIN2BNR1I3CDK5CDK5R1
SCHEMBL20781187 0.81 NR1I3 (1.00) GRIN1GRIN2BNR1I3CDK5CDK5R1
SCHEMBL21802632 0.81 NR1I3 (1.00) GRIN1GRIN2BNR1I3CDK5CDK5R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0285383-A2 Treatment of prostatic carcinoma with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones MERCK & CO. INC. (US) 1988-10-05 EP disclosed
EP-0285382-A2 Treatment of androgenic alopecia with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones MERCK & CO. INC. (US) 1988-10-05 EP disclosed